Welcome to our dedicated page for NeOnc Technologies Holdings SEC filings (Ticker: NTHI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The NeOnc Technologies Holdings, Inc. (NTHI) SEC filings page on Stock Titan aggregates the company’s regulatory disclosures as a Nasdaq-listed issuer focused on central nervous system therapeutics. NeOnc’s filings, including Forms 8‑K and its registration statement on Form S‑1, provide structured insight into its CNS oncology pipeline, corporate transactions and capital structure.
Through recent 8‑K filings, NeOnc has furnished press releases and supporting materials describing updated Phase 1/2a and Phase 2a clinical results for intranasal NEO100 in recurrent WHO Grade III/IV IDH1‑mutant astrocytoma, including radiographic response data, progression-free survival and long-term survival metrics, as well as safety observations. Other 8‑K reports outline U.S. Food and Drug Administration authorization to proceed with Phase IIa/IIb development of NEO212, a bio-conjugated chemotherapy candidate for primary and metastatic brain tumors.
Filings also detail material agreements and strategic initiatives, such as a Master Services Agreement with Insights Pharmaceutical Research LLC (IROS) to conduct multi-site clinical trials in the United Arab Emirates, the formation and role of the NuroMENA subsidiary, share exchange transactions, and acquisitions of entities like JandB Holdings, LLC. Additional disclosures cover executive appointments, equity incentive awards, bridge loans, lines of credit and other financing arrangements that support NeOnc’s clinical programs.
On Stock Titan, these filings are supplemented with AI-powered summaries that explain the significance of each document in accessible language. Users can quickly understand key points from lengthy registration statements, 8‑K event descriptions and related exhibits, helping them interpret how clinical data updates, regulatory decisions, financing structures and governance changes may relate to NTHI’s CNS oncology strategy. Real-time updates from EDGAR ensure that new NeOnc filings are incorporated as they become available, enabling efficient review of the company’s ongoing reporting history.
NeOnc Technologies Holdings, Inc. announced it will host an investor conference call and webcast on November 12, 2025 at 9:00 a.m. Eastern Time to present data updates from its ongoing Phase 1/2a NEO100-1 clinical trial and its compassionate use program.
The announcement was furnished under Item 7.01, and a related press release dated November 7, 2025 was attached as Exhibit 99.1.
NeOnc Technologies Holdings (NTHI) announced a leadership change. On October 31, 2025, Dr. Thomas Chen resigned as Chief Executive Officer and became Chief Medical Officer and Chief Scientific Officer, while remaining Vice Chairman. The Board appointed Amir Heshmatpour as Chief Executive Officer effective immediately; he also continues as President and Executive Chairman.
The Company agreed to pay Mr. Heshmatpour $1 per year until a formal employment agreement is finalized. He will be granted 1,200,000 shares of restricted stock under the 2023 plan, with one-half vesting on January 2, 2025 and the remainder vesting in twelve equal monthly installments thereafter.
The filing also summarizes prior related-party and financing items: AFH advisory fees of $500,000 in 2023 and an amended arrangement including an upfront payment of $2,500,000; a June 14, 2024 bridge loan conversion into 979,039 shares at $12 per share; an October 11, 2024 line of credit of up to $10.0 million at 10% interest with a warrant (cashlessly exercised for 164,500 shares in April 2025); and approximately $300,000 advanced in February 2025 with a 50% original issue discount, repaid after the direct listing.
NeOnc Technologies Holdings, Inc. (NTHI) announced a leadership change at its Middle East subsidiary. His Highness Sheikh Nahyan bin Zayed Al Nahyan will formally assume the role of Executive Chairman of NuroMENA Holdings Ltd., the company’s Middle East unit. The update was communicated via a press release.
The announcement was furnished under Item 7.01 and is not deemed “filed” under the Exchange Act. A copy of the press release is included as Exhibit 99.1.
NeOnc Technologies Holdings, Inc. reported that its previously announced $50 million strategic partnership is now expected to close no later than October 23, 2025, after receiving all required tax identification and regulatory approvals from the United Arab Emirates. This indicates the transaction has cleared key governmental and regulatory hurdles and is approaching completion.
The company shared this update through a press release furnished under a Regulation FD disclosure, meaning the information is being made broadly available to the market but is not treated as filed for liability purposes or automatically incorporated into other securities law documents unless specifically referenced.
NeOnc Technologies Holdings, Inc. has entered into a Master Services Agreement with Insights Pharmaceutical Research LLC (IROS), a UAE-based contract research organization affiliated with Group 42 Holding Ltd. and Mubadala Investment Company PJSC. Under this agreement, IROS will run clinical trials in the UAE for NeOnc, handling regulatory submissions, site selection and management, monitoring, data management and trial reporting in line with Good Clinical Practice and UAE/FDA rules.
The first work order covers a multi-site, randomized Phase 2b/3 study of intranasal NEO100 in patients with progressive or recurrent Grade III astrocytomas and glioblastoma multiforme, with an estimated budget of about $2.4 million in service fees and $0.1 million in pass-through costs, paid in four milestone-based installments. NeOnc keeps all rights to the clinical data, intellectual property and regulatory filings, and plans to transfer the MSA to its controlled UAE subsidiary, NuroCure, once that entity is incorporated.
NeOnc Technologies Holdings, Inc. filed a current report describing a regulatory milestone for its lead program. The company announced that the U.S. Food and Drug Administration has authorized it to proceed with Phase IIa/IIb of its NEO212-01 clinical trial, indicating clearance to advance this investigational therapy into the next stage of human testing. The update was communicated through a press release furnished as an exhibit to the report rather than filed for liability purposes under the securities laws.
NeOnc Technologies Holdings, Inc. (NTHI) Form 3 shows that Ishwar K. Puri, identified as a director, filed an initial Section 16 statement related to an 08/18/2025 event. The filing states explicitly that no securities are beneficially owned by the reporting person. The form is individually filed and bears the reporting person’s signature dated 09/05/2025. No non‑derivative or derivative holdings are listed on the schedules.
NeOnc Technologies Holdings, Inc. reported that it acquired 100% of JandB Holdings, LLC through a share exchange completed on August 18, 2025. The consideration is 120,000 shares of NeOnc common stock with an attributed value of $25 per share, reduced by a number of shares equal to transaction fees divided by $25. JandB is now a wholly owned subsidiary. The company also announced that director Dr. Ming-Fu Chiang resigned from the board, with no disagreement cited, and will continue on the science advisory board. On the same day, the board elected Ishwar Puri, a senior vice president for research and innovation at the University of Southern California and former engineering dean at McMaster University, as a director, in connection with the JandB transaction. NeOnc also issued a press release with second-quarter financial results, which is furnished as an exhibit.
NeOnc Technologies Holdings, Inc. completed a Nasdaq listing in March 2025 and received $11,644,005 from private placement commitments held in escrow until its registration became effective. For the three and six months ended June 30, 2025, the company reported net losses of $5,680,170 and $38,006,186, respectively, and an accumulated deficit of $88,614,631 at June 30, 2025. Shares outstanding were 19,026,776 at June 30, 2025 (18,090,526 at December 31, 2024). The company has material related-party obligations including an accrued advisory fee balance of $5,882,710 and an unpaid litigation settlement payable of $4,000,000. Financing activity includes bridge and promissory note arrangements with original issue discounts and subsequent issuance of promissory notes totaling $4,000,000 as of August 13, 2025. The filing discloses significant accumulated losses, ongoing financing arrangements, and contingent obligations that affect liquidity.
NeOnc Technologies Holdings, Inc. filed an 8-K dated August 18, 2025 reporting a material event: a declaration of non-reliance on previously issued financial statements or a related audit report or completed interim review. The filing is signed by Amir Heshmatpour. The notice is brief and does not include financial tables, earnings data, or details explaining the reasons for the non-reliance statement. The disclosure indicates the company has identified an issue significant enough to withdraw confidence in earlier financial reporting, but the document provides no additional context, corrective actions, timelines, or quantified impacts.